Zobrazeno 1 - 10
of 427
pro vyhledávání: '"Vicente E, Torres"'
Autor:
Ronald D. Perrone, Dorothee Oberdhan, John Ouyang, Daniel G. Bichet, Klemens Budde, Arlene B. Chapman, Berenice Y. Gitomer, Shigeo Horie, Albert C.M. Ong, Vicente E. Torres, A. Neil Turner, Holly Krasa
Publikováno v:
Kidney International Reports, Vol 8, Iss 5, Pp 989-1001 (2023)
Introduction: The course of autosomal dominant polycystic kidney disease (ADPKD) varies greatly among affected individuals, necessitating natural history studies to characterize the determinants and effects of disease progression. Therefore, we condu
Externí odkaz:
https://doaj.org/article/6263893d07674a6789c237002dc53cb4
Autor:
Julie Xia Zhou, Alice Shasha Cheng, Li Chen, Linda Xiaoyan Li, Ewud Agborbesong, Vicente E. Torres, Peter C. Harris, Xiaogang Li
Publikováno v:
Cells, Vol 13, Iss 6, p 489 (2024)
The progression of autosomal dominant polycystic kidney disease (ADPKD), an inherited kidney disease, is associated with renal interstitial inflammation and fibrosis. CD74 has been known not only as a receptor of macrophage migration inhibitory facto
Externí odkaz:
https://doaj.org/article/07564befe01d476eb3e7cebc11e020e1
Autor:
Dalia Zubidat, Christian Hanna, Amarjyot K. Randhawa, Byron H. Smith, Maroun Chedid, Daniel-Hasan N. Kaidbay, Luca Nardelli, Yaman G. Mkhaimer, Reem M. Neal, Charles D. Madsen, Sarah R. Senum, Adriana V. Gregory, Timothy L. Kline, Ziad M. Zoghby, Stephen M. Broski, Naim S. Issa, Peter C. Harris, Vicente E. Torres, Jad G. Sfeir, Fouad T. Chebib
Publikováno v:
Bone Reports, Vol 18, Iss , Pp 101655- (2023)
ADPKD is caused by pathogenic variants in PKD1 or PKD2, encoding polycystin-1 and -2 proteins. Polycystins are expressed in osteoblasts and chondrocytes in animal models, and loss of function is associated with low bone mineral density (BMD) and volu
Externí odkaz:
https://doaj.org/article/f14b4e1338eb4ca6b2a406927c9c0dc0
Autor:
Ronald D. Perrone, Ali Hariri, Pascal Minini, Curie Ahn, Arlene B. Chapman, Shigeo Horie, Bertrand Knebelmann, Michal Mrug, Albert C.M. Ong, York P.C. Pei, Vicente E. Torres, Vijay Modur, Ronald T. Gansevoort
Publikováno v:
Kidney Medicine, Vol 4, Iss 10, Pp 100538- (2022)
Rationale & Objective: Venglustat, a glucosylceramide synthase inhibitor, inhibits cyst growth and reduces kidney failure in mouse models of autosomal dominant polycystic kidney disease (ADPKD). STAGED-PKD aims to determine the safety and efficacy of
Externí odkaz:
https://doaj.org/article/66ff3b0e6417477da59ccf6a9cdbba1d
Autor:
Xia Zhou, Vicente E. Torres
Publikováno v:
Frontiers in Molecular Biosciences, Vol 9 (2022)
Autosomal dominant polycystic kidney disease (ADPKD), with an estimated genetic prevalence between 1:400 and 1:1,000 individuals, is the third most common cause of end stage kidney disease after diabetes mellitus and hypertension. Over the last 3 dec
Externí odkaz:
https://doaj.org/article/f62622295b474306ada4df15a05ef9eb
Autor:
Peter Janssens, Jean-Paul Decuypere, Stéphanie De Rechter, Luc Breysem, Dorien Van Giel, Jaak Billen, An Hindryckx, Luc De Catte, Marcella Baldewijns, Kathleen B.M. Claes, Karl M. Wissing, Koen Devriendt, Bert Bammens, Isabelle Meyts, Vicente E. Torres, Rudi Vennekens, Djalila Mekahli
Publikováno v:
Kidney International Reports, Vol 6, Iss 6, Pp 1687-1698 (2021)
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) causes kidney failure typically in adulthood, but the disease starts in utero. Copeptin, epidermal growth factor (EGF), and monocyte chemoattractant protein-1 (MCP-1) are associated w
Externí odkaz:
https://doaj.org/article/ef2893b628a349dbbf02ab11b7ecada7
Autor:
Mireille El Ters, Pengcheng Lu, Jonathan D. Mahnken, Jason R. Stubbs, Shiqin Zhang, Darren P. Wallace, Jared J. Grantham, Arlene B. Chapman, Vicente E. Torres, Peter C. Harris, Kyongtae Ty Bae, Douglas P. Landsittel, Frederic F. Rahbari-Oskoui, Michal Mrug, William M. Bennett, Alan S.L. Yu
Publikováno v:
Kidney International Reports, Vol 6, Iss 4, Pp 953-961 (2021)
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth and a loss of functioning renal mass, but a decline in glomerular filtration rate (GFR) and onset of end-stage renal disease (ESRD) occur l
Externí odkaz:
https://doaj.org/article/8beb5b69c3a14ce4bc60ffbad23c4ea5
Autor:
Andrew J. Mallett, Ronald D. Perrone, Gopala Rangan, Carmel Hawley, Ragada El-Damanawi, Thomas F. Hiemstra, Carolina Townsend Arellano, Jennifer Lee, Vicente E. Torres
Publikováno v:
Kidney International Reports, Vol 6, Iss 4, Pp 1032-1040 (2021)
Introduction: In pivotal trials of patients with autosomal dominant polycystic kidney disease at risk of rapid progression, tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in early-to-moderate (TEMPO 3:4 [NCT00428948]) and modera
Externí odkaz:
https://doaj.org/article/f06670cb82e94a83981fe34ce5017a8f
Autor:
Christian Hanna, Theodora A. Potretzke, Maroun Chedid, Laureano J. Rangel, Jennifer Arroyo, Dalia Zubidat, Peter J. Tebben, Andrea G. Cogal, Vicente E. Torres, Peter C. Harris, David J. Sas, John C. Lieske, Dawn S. Milliner, Fouad T. Chebib
Publikováno v:
Kidney Medicine, Vol 4, Iss 3, Pp 100419- (2022)
Rationale & Objective: Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is a rare monogenic disorder caused by SLC34A3 pathogenic variants. HHRH is characterized by kidney phosphate wasting, hypophosphatemia, hypercalciuria, an elevated
Externí odkaz:
https://doaj.org/article/fb2b003278e2450194649456f90f450b
Publikováno v:
Kidney International Reports, Vol 5, Iss 5, Pp 727-731 (2020)
Externí odkaz:
https://doaj.org/article/f6e484ad91a448c88269bf2f616df4b2